OmniAb Inc
OABI
View Detailed Chart
1.700USD
+0.050+3.03%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
244.72MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.03%
5 Days
-6.59%
1 Month
-7.61%
6 Months
-11.92%
Year to Date
-8.11%
1 Year
-54.18%
View Detailed Chart
TradingKey Stock Score of OmniAb Inc
Currency: USD Updated: 2026-02-06Key Insights
OmniAb Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 124 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.33.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
OmniAb Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
OmniAb Inc Highlights
StrengthsRisks
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Growing
The company is in a growing phase, with the latest annual income totaling USD 26.39M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 26.39M.
Overvalued
The company’s latest PE is -2.89, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.79M shares, decreasing 21.46% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 95.33K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.18.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.333
Target Price
+344.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
OmniAb Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
OmniAb Inc Info
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Ticker SymbolOABI
CompanyOmniAb Inc
CEOFoehr (Matthew William)
Websitehttps://www.omniab.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70075.280
+105.150 (+0.15%)
282.580
+22.390 (+8.61%)
2079.010
+27.280 (+1.33%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
